These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29700927)

  • 1. Effects of an orexin receptor antagonist on blood pressure and metabolic parameters.
    Moriyama S; Yanai H; Takeuchi Y; Hayakawa T
    J Clin Hypertens (Greenwich); 2018 May; 20(5):978-980. PubMed ID: 29700927
    [No Abstract]   [Full Text] [Related]  

  • 2. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
    James MH; Fragale JE; Aurora RN; Cooperman NA; Langleben DD; Aston-Jones G
    Neuropsychopharmacology; 2020 Apr; 45(5):717-719. PubMed ID: 31986520
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders.
    Tsuneki H; Wada T; Sasaoka T
    Pharmacol Ther; 2018 Jun; 186():25-44. PubMed ID: 29289556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

  • 5. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new class of sedative/hypnotics: dual orexin receptor antagonists.
    Simonson W
    Geriatr Nurs; 2014; 35(6):462-3. PubMed ID: 25457290
    [No Abstract]   [Full Text] [Related]  

  • 7. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
    Campbell EJ; Marchant NJ; Lawrence AJ
    Brain Res; 2020 Mar; 1731():145902. PubMed ID: 30081035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
    Tsuneki H; Kon K; Ito H; Yamazaki M; Takahara S; Toyooka N; Ishii Y; Sasahara M; Wada T; Yanagisawa M; Sakurai T; Sasaoka T
    Endocrinology; 2016 Nov; 157(11):4146-4157. PubMed ID: 27631554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.
    Petrous J; Furmaga K
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 29066641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suvorexant (Belsomra) for insomnia.
    Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996
    [No Abstract]   [Full Text] [Related]  

  • 13. Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.
    Cabanas M; Pistono C; Puygrenier L; Rakesh D; Jeantet Y; Garret M; Cho YH
    Neurotherapeutics; 2019 Jul; 16(3):784-796. PubMed ID: 30915710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights on the potential effect of orexin receptor antagonist suvorexant on Parkinson's disease symptoms.
    Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Saad HM; Batiha GE
    Neurol Sci; 2024 May; 45(5):2367-2368. PubMed ID: 38231375
    [No Abstract]   [Full Text] [Related]  

  • 16. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
    Campbell EJ; Norman A; Bonomo Y; Lawrence AJ
    Brain Res; 2020 Feb; 1728():146597. PubMed ID: 31837287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of switching to suvorexant for mild primary insomnia when sleepwalking episodes occur during zolpidem treatment.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Dec; 30():122-123. PubMed ID: 28898806
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 19. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.
    Hamuro A; Honda M; Wakaura Y
    Aust N Z J Psychiatry; 2018 Feb; 52(2):207-208. PubMed ID: 29237271
    [No Abstract]   [Full Text] [Related]  

  • 20. Benefits associated with switching from benzodiazepine hypnotics to suvorexant in patients with mild primary insomnia.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Oct; 29():71-72. PubMed ID: 29061431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.